These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33313046)

  • 1. Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study.
    Leuschner G; Klotsche J; Kreuter M; Prasse A; Wirtz H; Pittrow D; Frankenberger M; Behr J; Kneidinger N;
    Front Med (Lausanne); 2020; 7():601279. PubMed ID: 33313046
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.
    Behr J; Prasse A; Wirtz H; Koschel D; Pittrow D; Held M; Klotsche J; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Kahn N; Welte T; Neurohr C; Schwaiblmair M; Bahmer T; Oqueka T; Frankenberger M; Kreuter M
    Eur Respir J; 2020 Aug; 56(2):. PubMed ID: 32381492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry.
    Kreuter M; Swigris J; Pittrow D; Geier S; Klotsche J; Prasse A; Wirtz H; Koschel D; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Kahn N; Welte T; Neurohr C; Schwaiblmair M; Held M; Bahmer T; Oqueka T; Frankenberger M; Behr J
    Respir Res; 2019 Mar; 20(1):59. PubMed ID: 30876420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry.
    Glaspole IN; Chapman SA; Cooper WA; Ellis SJ; Goh NS; Hopkins PM; Macansh S; Mahar A; Moodley YP; Paul E; Reynolds PN; Walters EH; Zappala CJ; Corte TJ
    Respirology; 2017 Jul; 22(5):950-956. PubMed ID: 28166611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly.
    Honda K; Saraya T; Ishii H
    J Clin Med; 2023 May; 12(10):. PubMed ID: 37240670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
    Maher TM; Strek ME
    Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan.
    Iwasaki K; Wakabayashi H; Saiki A; Ueshiba H; Murakami Y; Matsuzawa Y
    Drugs Real World Outcomes; 2024 Mar; 11(1):43-52. PubMed ID: 37883007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.
    Nambiar AM; Anzueto AR; Peters JI
    PLoS One; 2017; 12(4):e0176312. PubMed ID: 28441449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial Alarmins in Serum and Exhaled Breath in Patients with Idiopathic Pulmonary Fibrosis: A Prospective One-Year Follow-Up Cohort Study.
    Majewski S; Szewczyk K; Białas AJ; Miłkowska-Dymanowska J; Górski P; Piotrowski WJ
    J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31581688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
    Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
    BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment.
    Balestro E; Cocconcelli E; Giraudo C; Polverosi R; Biondini D; Lacedonia D; Bazzan E; Mazzai L; Rizzon G; Lococo S; Turato G; Tinè M; Cosio MG; Saetta M; Spagnolo P
    J Clin Med; 2019 Sep; 8(9):. PubMed ID: 31540181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of antifibrotic agents in idiopathic pulmonary fibrosis after initiation of long-term oxygen therapy.
    Ishiwari M; Kono Y; Togashi Y; Kobayashi K; Kikuchi R; Kogami M; Abe S
    Sarcoidosis Vasc Diffuse Lung Dis; 2024 Mar; 41(1):e2024002. PubMed ID: 38567555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics, comorbidities, and outcomes in patients with idiopathic pulmonary fibrosis.
    Alhamad EH; Cal JG; Alrajhi NN; Aharbi WM; AlRikabi AC; AlBoukai AA
    Ann Thorac Med; 2020; 15(4):208-214. PubMed ID: 33381235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry.
    Jegal Y; Park JS; Kim SY; Yoo H; Jeong SH; Song JW; Lee JH; Lee HL; Choi SM; Kim YW; Kim YH; Choi HS; Lee J; Uh ST; Kim TH; Kim SH; Lee WY; Kim YH; Lee HK; Lee EJ; Heo EY; Yang SH; Kang HK; Chung MP;
    Tuberc Respir Dis (Seoul); 2022 Apr; 85(2):185-194. PubMed ID: 34902237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
    Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
    Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
    Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
    Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis.
    Lassenius MI; Toppila I; Pöntynen N; Kasslin L; Kaunisto J; Kilpeläinen M; Laitinen T
    Eur Clin Respir J; 2020; 7(1):1702618. PubMed ID: 32002175
    [No Abstract]   [Full Text] [Related]  

  • 19. Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study.
    Jovanovic DM; Šterclová M; Mogulkoc N; Lewandowska K; Müller V; Hájková M; Studnicka M; Tekavec-Trkanjec J; Littnerová S; Vašáková M;
    Respir Res; 2022 May; 23(1):135. PubMed ID: 35624513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment.
    Kølner-Augustson L; Prior TS; Skivild V; Aalestrup A; Bendstrup E
    Eur Clin Respir J; 2020 Nov; 8(1):1853658. PubMed ID: 33312458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.